http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#Head
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#assertion
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#provenance
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#pubinfo
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#assertion
http://purl.obolibrary.org/obo/DOID_10763
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_10763
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00388
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association
http://www.w3.org/2000/01/rdf-schema#label
"Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension, or thyrotoxicosis. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [ 4.1 Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [ 4.2 Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension or thyrotoxicosis. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients [See Dosage and Administration section"
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00388
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#provenance
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#pubinfo
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#sig
http://purl.org/nanopub/x/hasSignature
CeVfrWlunG5MuE0AHRsdOCenuiibn2U8HgL48VA+FKnlAeC0uC9xqskTjEhrPwaRlnTRgF201nRV6oMPOW1rI15fJgbIFC7bT98K2ngbhUqwx6ebjQ+FE6T7pYjXBSRh7lyBkRCuD8pADJKt7M/mD9cPEa6WC7iBC2XPRCOwuAw=
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg
http://purl.org/dc/terms/created
2021-08-25T13:33:11.099+02:00
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY